Ocugen enters partnership with CanSinoBIO, completes Histogenics merger

Ocugen announced a strategic partnership with CanSino Biologics for gene therapy candidates and also the completion of its merger with Histogenics.
CanSinoBIO will provide CMC development and clinical supplies for the development of OCU400, Ocugen’s first gene therapy product in its modifier gene therapy platform, according to a press release. The agreement provides commercialization rights to CanSinoBIO in greater China and allows CanSinoBIO the option to support commercial manufacture for Ocugen.
Ocugen has received orphan drug designations for OCU400 for the treatment of NR3E3

Full Story →